CXC chemokine ligand-13 (CXCL13) has been implicated in oral squamous cell carcinoma (OSCC) tumor progression and osteolysis. The tumor necrosis factor family member RANKL (receptor activator of NF-kB ligand), a critical bone resorbing osteoclastogenic factor, has an important role in cancer invasion of bone/osteolysis. Here, we show high-level expression of CXCL13 in primary human OSCC tumor specimens; however, human bone marrow-derived stromal (SAKA-T) and murine preosteoblast (MC3T3-E1) cells produce at very low level. Recombinant CXCL13 (0 --15 ng/ml) dose dependently induced CXCR5 expression in SAKA-T and MC3T3-E1 cells. Conditioned media obtained from OSCC cell lines increased the RANKL expression and an antibody against the CXCL13 specific receptor, CXCR5 markedly decreased RANKL expression in these cells. Furthermore, CXCL13 increased hRANKL-Luc promoter activity. Superarray screening identified c-Myc and NFATc3 transcription factors upregulated in CXCL13-stimulated SAKA-T cells. Immunohistochemical analysis of OSCC tumors that developed in athymic mice demonstrated RANKL and NFATc3 expression in tumor and osteoblast cells, however, showed p-c-Myc expression specific to osteoblastic cells at the tumor --bone interface. We further identified NFATc3 expression, but not c-Myc activation in primary human OSCC tumor specimens compared with adjacent normal tissue. Also, CXCL13 significantly increased p-ERK1/2 in SAKA-T and MC3T3-E1 cells. siRNA suppression of c-Myc expression markedly decreased CXCL13-induced RANKL and NFATc3 expression in preosteoblast cells. Chromatin-immuno precipitation assay confirmed p-c-Myc binding to the hRANKL promoter region. In summary, c-Myc activation through CXCL13 --CXCR5 signaling axis stimulates RANKL expression in stromal/ preosteoblast cells. Thus, our results implicate CXCL13 as a potential therapeutic target to prevent OSCC invasion of bone/ osteolysis.
INTRODUCTION
Head and neck squamous cell carcinoma contributes to approximately 3% of all malignancies in the United States. 1 Oral squamous cell carcinoma (OSCC), which contributes to 40% of all head and neck squamous cell carcinoma, is associated with mucosal surfaces of the oral cavity and oropharynx. 2 The etiology of OSCC involves multiple genetic alterations and an exposure to environmental carcinogens, such as tobacco, alcohol, chronic inflammation and viral infections. 3 OSCC tumor cells have been shown to invade maxillary and mandibular bone in a murine model. 4 Nuclear factor kappaB (NF-kB) expression is upregulated in OSCC gradually from premalignant lesions to invasive cancer. 5 Hepatocyte growth factor through upregulation of matrix metalloproteinases, such as MMP-1 and MMP-9, promotes OSCC tumor invasion. 6 Thus, malignant OSCC tumors potently invade local bone; however, the molecular mechanisms of tumorassociated osteolysis of bone are unclear.
The tumor necrosis factor (TNF) family member, receptor activator of NF-kB ligand (RANKL), which is expressed on marrow stromal/preosteoblast cells in response to several osteotropic factors, is critical for osteoclast precursor differentiation to form multinucleated osteoclasts that resorb bone. 7 Osteoclast activation has an important role in several malignancies, including oral cancer invasion of bone and metastasis. 8 Also, MMP-7 produced by osteoclasts at the prostate tumor --bone interface has been shown to promote osteolysis through solubilization of RANKL. 9 Furthermore, altered RANKL and osteoprotegerin expression in OSCC cells facilitate osteoclastogenesis at the tumor --bone microenvironment. 10 Thus, RANKL expression in the tumor --bone microenvironment has an important role in cancer invasion of the bone.
Chemokines are a superfamily of small cytokine-like proteins that interact with seven-transmembrane-domain glycoprotein receptors coupled to the G protein signaling pathway, which selectively attract and activate different cell types. 11 CXC chemokines represent a subfamily with first two of four invariant cysteine residues separated by a single amino acid and have an important role in the regulation of angiogenesis, tumor immunity and organ-specific metastasis. 12, 13 CXC chemokine ligand-13 (CXCL13) that binds monogamously to the CXC chemokine receptor-5 (CXCR5) is involved in B-cell chemotaxis and is induced under inflammatory conditions. 14 It has been shown that inflammatory cytokines, such as interleukin (IL)-1b and TNF-a, differentially modulate CXCL13 production in stromal and osteoblast cells derived from osteoarthritis patients. 15 Similarly, IL-6 treatment significantly induced CXCL13 expression in human bone marrow endothelial cells and osteoblast cells, but not osteoclasts. 16 Furthermore, head and neck squamous cell carcinoma has been reported to predominantly express chemokine receptors such as CCR7 and CXCR5; however, CXCR4 expression is low or undetectable. 17 Microarray analysis for gene expression profiling in OSCC identified high levels of CXCL13 expression, which is implicated in OSCC development and progression. 18, 19 Recently, we showed nuclear factor of activated T-cells, cytoplasmic 3 (NFATc3), which is a downstream target of the CXCL13 signaling axis, to stimulate RANKL expression in OSCC cells. 20 Here, we report that CXCL13 activation of c-Myc induces RANKL expression in stromal/preosteoblast cells, which implicate CXCL13 as a potential therapeutic target to prevent OSCC invasion of bone/osteolysis.
RESULTS
CXCL13 expression in primary human OSCC and bone marrow stromal/preosteoblast cells We recently identified high levels of CXCL13 secretion in OSCCderived cell lines and further demonstrated a functional role in tumor invasion of bone/osteolysis in athymic mice. 21 In this study, immunohistochemical staining using a tissue microarray (TMA) of 60 human OSCC tumor specimens identified that 495% of OSCC stained strong positive for CXCL13 expression; however, a very low-level expression was detected in normal adjacent tissue ( Figure 1a) . We next measured the levels of CXCL13 in conditioned media (CM) obtained from the human bone marrow-derived stromal cell line (SAKA-T) 22 and murine preosteoblast (MC3T3-E1) cells compared with OSCC tumor-derived cell line (SCC-14a) by enzyme-linked immunosorbent assay (ELISA). We demonstrated that SAKA-T and MC3T3-E1 cells produced very low levels (10 pg/ ml) of CXCL13 compared with SCC-14a CM (120 pg/ml) ( Figure 1b) . We then examined whether CXCL13 stimulates the CXCL13-specific receptor, CXCR5 expression in bone marrow stromal/ preosteoblast cells. Western blot analysis of total cell lysates obtained from SAKA-T and MC3T3-E1 cells stimulated with CXCL13 (15 ng/ml) indicated a time-dependent increase in CXCR5 expression ( Figure 1c ). These results suggest that OSCC secretion of CXCL13 at high levels modulates CXCR5 expression in stromal/ preosteoblast cells.
CXCL13 stimulation of RANKL expression in stromal/preosteoblast cells Previously, we showed CXCL13 stimulation of RANKL, a critical osteoclastogenic factor expression in OSCC cells. 20 We, therefore, examined the potential of OSCC CM to stimulate RANKL expression in bone marrow-derived stromal/preosteoblast cells. Real-time reverse-transcription PCR (RT --PCR) analysis of total RNA isolated from MC3T3-E1 preosteoblast cells stimulated with CM (0 --30%) obtained from OSCC cell lines (SCC-1, SCC-11B and SCC14a) demonstrated a dose-dependent increase in RANKL mRNA expression. We further demonstrated that anti-CXCR5 antibody abolished SCC-14a CM (20%) and recombinant CXCL13 (15 ng/ml) induced RANKL expression in SAKA-T and MC3T3-E1 cells (Figure 2a ). In addition, cells stimulated with different concentrations (0 --15 ng/ml) of CXCL13 revealed a dose-dependent increase in RANKL mRNA expression (Figure 2b ). Western blot analysis of total cell lysates obtained from SAKA-T, MC3T3-E1 and primary mouse bone marrow-derived stromal cells further confirmed CXCL13 stimulation of RANKL expression (Figure 2c ). These results indicate that OSCC secretion of CXCL13 stimulates RANKL expression in stromal/preosteoblast cells. CXCL13 transcriptional control of RANKL gene expression in stromal/preosteoblast cells To determine the CXCL13 transcriptional control of RANKL expression, SAKA-T and MC3T3-E1 cells were transiently transfected with hRANKL-luciferase reporter plasmid (hRANKL P#3) by lipofectamine and treated with CXCL13 (0 --15 ng/ml) for 6 h. Cells that were mock transfected with the empty vector served as controls. CXCL13 treatment dose-dependently increased the hRANKL gene promoter activity in SAKA-T and MC3T3-E1 cells (Figure 3a and b) . To further examine the CXCL13 transcriptional control of RANKL gene expression, we performed SuperArray screening for transcription factors. SAKA-T cells were stimulated with CXCL13 (15 ng/ml) for 6 h and total RNA isolated was used as template for SuperArray screening with real-time RT --PCR and data obtained were analyzed by a web portal as described in methods. We thus identified CXCL13 upregulation of c-Myc (4-fold) and NFATc3 (4.5-fold) transcription factors, which have consensus binding motifs in the hRANKL promoter region (data not shown). 23 To further validate these results, total cell lysates obtained from MC3T3-E1 cells stimulated with different concentrations of CXCL13 (0 --20 ng/ml) for 6 h were analyzed by western blot. CXCL13 treatment resulted in a dose-dependent increase in c-Myc, NFATc3 and RANKL expression in these cells (Figure 3c ). DISCUSSION RANKL-RANK signaling is critical for osteoclast development and bone resorption activity. 7 RANKL has been implicated as the prognostic marker and therapeutic target for cancer metastasis. 24 --26 Also, CXCL13 has been identified as a prognostic marker in OSCC development. 19 We demonstrated CXCL13 expression in primary human OSCC tumor specimens consistent with microarray profiling of gene expression in OSCC. 18 In contrast to OSCC cells, stromal/preosteoblast cells produced low levels of CXCL13. However, human osteoblasts have been shown to express functional CXCR5 receptors. 27 Our findings that OSCC production of CXCL13, which induces CXCR5 expression, suggest a paracrine regulation in these cells. Furthermore, CXCL13 stimulation of RANKL expression in stromal/preosteoblast cells facilitates osteoclast activation and tumor invasion of bone/osteolysis. We recently identified elevated osteoclast formation/activity at OSCC tumor --bone microenvironment in athymic mice.
21
CXCL13 has been shown to be involved in prostate cancer progression and invasion through extracellular signal-regulated kinases (ERK) activation. 28 Further, lipopolysaccharide treatment of osteoblasts induced RANKL expression in an ERK-activationdependent manner. 29 In addition, ERK signaling has been shown to promote c-Myc expression and activity in rhabdomyosarcoma tumor cells. 30 Therefore, CXCL13 activation of ERK1/2 may have an important role in c-Myc and RANKL expression in stromal/ preosteoblast cells. Tumor-derived cytokines such as parathyroid hormone, IL-1b and prostaglandin E2 have been shown to upregulate RANKL expression in bone marrow stromal/osteoblast cells. 31 --33 Furthermore, OSCC production of osteotropic cytokines and stimulation of stromal cells to synthesize IL-6 in the tumor --bone microenvironment favors osteoclast formation/activation. 34 Therefore, it is possible that OSCC production of osteotropic cytokines regulate RANKL expression independent of the CXCL13-CXCR5 signaling axis in stromal/preosteoblast cells. However, CXCL13 upregulation of hRANKL promoter activity in stromal/preosteoblast cells indicate CXCL13-CXCR5 signaling axis It has been demonstrated that increased RANKL expression in stromal cells results in excess bone resorption in multiple myeloma. 35 Also, RANKL expression in fibroblastic cells in human gingival squamous cell carcinomas is implicated in bone invasion. 36 In addition, prostate tumor cells and osteoclast production of MMP-7 has been shown to contribute to tumorinduced osteolysis through solubilization of RANKL in the tumor --bone microenvironment. 37 Similarly, tumor cell interaction with osteoclasts results in the upregulation of cathepsin G expression, which promotes tumor osteolysis through solubilization of RANKL. 38 Therefore, OSCC production of matrix metalloproteases may increase soluble RANKL, which promote tumor invasion of bone. This study further identifies that CXCL13 induces c-Myc and NFATc3 expression in stromal/preosteoblast cells; however, c-Myc activation is specific in preosteoblast cells at the tumor --bone interface. Variable levels of c-Myc expression has been reported in OSCC tumors at different stages. 39 In this study, we observe the lack of c-Myc activation in primary OSCC specimens from human subjects and mouse xenograft model. NFATc1 regulates c-Myc gene transcription in pancreatic cancer cells. 40 Conversely, c-Myc expression has been shown to increase intracellular calcium levels and NFAT activation in B lymphocytes. 41 Also, sequential induction of NFAT and c-Myc by TGF-b promote cancer cell proliferation. 42 In this study, we show that siRNA suppression of c-Myc inhibits CXCL13-induced NFATc3 and RANKL expression indicating that c-Myc activation is critical for RANKL expression in stromal/preosteoblast cells. Thus, our findings are novel that CXCL13 production by OSCC cells stimulates RANKL expression in bone marrow stromal/preosteoblast cells and c-Myc is a downstream target of the CXCL13/CXCR5 axis to stimulate RANKL expression. Collectively, our studies implicate CXCL13 as a potential therapeutic target to prevent OSCC invasion of bone/osteolysis.
MATERIALS AND METHODS

Reagents and antibodies
Cell culture and DNA transfection reagents were purchased from Invitrogen (Carlsbad, CA, USA). E. coli-derived recombinant human CXCL13 (purity 495%), anti-CXCR5, anti-human RANKL antibodies and CXCL13 ELISA kits were purchased from R&D systems (Minneapolis, MN, USA). AntiNFATc3, anti-c-Myc, anti-ERK, anti-p-ERK, peroxidase-conjugated secondary antibodies and siRNA against NFATc3 and c-Myc were purchased from Santa Cruz Biotechnology, Santa Cruz, CA, USA. Anti-p-c-Myc was purchased from Cell Signaling Technology (Danvers, MA, USA). 
OSCC cell culture
Human OSCC tumor-derived SCC-1, SCC-11B and SCC-14a cell lines 43 were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 100 units/ml penicillin/streptomycin in a humidified atmosphere with 5% CO 2 at 37 1C. In sub-confluent state, cells were washed twice with PBS and once with serum-free Dulbecco's modified Eagle's medium, and subsequently cultured in serum-free Dulbecco's modified Eagle's medium for 24 h. The CM collected was centrifuged to eliminate intact cells, debris and stored at À80 1C for further use.
Bioluminescence imaging SCC-11B cells (7 Â 10 6 ) stably transfected with RANKL-luciferase construct were injected subcutaneously (n ¼ 10) in PBS overlaying the calvaria of NCrnu/nu athymic mice, aged 4 --6 weeks (NCI, Frederick, MD, USA) and injected with PBS alone served as control group (n ¼ 8). At the end of the experimental period, mice received D-luciferin (150 mg/kg, i.p.) under 1 --2% inhaled isoflurane anesthesia. The bioluminescence signals were monitored using the IVIS system 200 series consisting of a highly sensitive cooled charge-coupled device camera and Living Image software (Xenogen Corp., Alameda, CA, USA) was used to grid the imaging data and integrates the total bioluminescence signals in each boxed region. Two kinetic bioluminescent acquisitions were collected between 0 and 20 min after Dluciferin injection to confirm the peak photon emission recorded as maximum photon efflux per second. All fluorescence images were acquired with a 15 s exposure. Data were analyzed using the total photon flux emission (photons/s) in the regions of interest covering the entire calvarial region. All the animal procedures were performed following the Institutional Animal Care and Use Committee (IACUC) approved protocol.
Quantification of CXCL13
CXCL13 levels in serum-free CM from SCC-14a, human bone marrowderived stromal cell line (SAKA-T) and mouse preosteoblast cell line (MC3T3-E1) was measured using the human and mouse specific ELISA kits (R&D systems) following the manufacturer's protocol.
Immunohistochemistry
Tissue microarray of 60 primary human OSCC tumors specimens were obtained from the Head and Neck Cancer Tissue Array Initiative at the NIDCR, NIH 44 and 8 control adjacent normal tissues were obtained from the Hollings Cancer Center Tissue Biorepository in accordance with an Institutional Review Board (IRB) approved protocol. Formalin-fixed OSCC tumor specimens from athymic mice or human subjects were processed for paraffin sectioning. Serial 5-mM sections were cut on a modified Leica RM 2155 rotary microtome (Leica Microsystems, Richmond Hill, ON, Canada). Antigen retrieval was performed with Target Retrieval Solution (DAKO, Carpinteria, CA, USA) coupled with steaming. The slides were incubated with primary anti-CXCL13, anti-NFATc3, anti-RANKL and anti-pc-Myc antibodies for 60 min at room temperature. Immunohistochemical staining was performed with HRP-labeled secondary antibody and diaminobenzidine (Vector Laboratories, Burlingame, CA, USA). The slides were briefly counterstained with hematoxylin and dehydrated through graded alcohols to xylene, and were cover slipped with a permanent mounting media.
Quantitative real-time RT --PCR RANKL mRNA expression levels were measured by real-time RT --PCR as described earlier. 20 Briefly, total RNA was isolated from SAKA-T and MC3T3-E1 cells treated with/without different concentrations of CM (0 --30%) obtained from OSCC cell lines or recombinant CXCL13 (0 --15 ng/ml) for 6 h using RNAzol reagent (Biotecx Labs, Houston, TX, USA). To eliminate the residual genomic DNA contamination, total RNA was treated with DNAse I (Sigma) at room temperature for 15 min followed by 10 min at 65 o C with the addition of 25 mM EDTA. The RNA integrity of samples was evaluated on the basis of the intensity of 28s and 18s rRNA bands on agarose gels and A 260 /A 280 ratio between 1.8 and 2.0. The reverse transcription reaction was performed using poly-dT primer and Moloney murine leukemia virus reverse transcriptase (Applied Biosystems, Foster City, CA, USA) in a 25 ml reaction volume containing total RNA (2 mg), 1 Â PCR buffer and 2 mM MgCl 2 , at 42 1C hRANKL promoter-luciferase reporter gene assay SAKA-T cells were cultured in a-MEM and MC3T3-E1 cells were cultured in a-MEM containing ribonucleosides and deoxyribonucleosides without ascorbic acid. The media were supplemented with 10% fetal bovine serum, 100 units/ml penicillin/streptomycin and cells were cultured in a humidified atmosphere with 5% CO 2 at 37 1C. hRANKL promoter-luciferase reporter plasmid (hRANKL P#3) construct 23 was transiently transfected into SAKA-T and MC3T3-E1 cells using lipofectamine. The transfection efficiency was normalized by co-transfection with 0.2 mg of pRSV b-gal plasmid and b-galactosidase activity was measured in the cells (Promega). LacZ cytochemical activity staining (Invitrogen, San Diego, CA) indicated the DNA transfection efficiency 480% in these cells. Cells were stimulated with E. coli-expressed recombinant hCXCL13 (0 --15 ng/ml) for 6 h. Cell monolayer was washed twice with PBS and incubated at room temperature for 15 min with 0.3 ml cell lysis reagent. A 20-ml aliquot of each sample was mixed with 100 ml of the luciferase assay reagent. The light emission was measured for 10 s of integrated time using a Sirius Luminometer following the manufacturer 0 s instructions (Promega).
Western blot analysis SAKA-T and MC3T3-E1 cells were seeded (5 Â 10 5 cells per well) in 6-well plates and supplemented with a-MEM-containing 10% fetal bovine serum. Cells were stimulated with or without CXCL13 as indicated and total cell lysates were prepared in a buffer containing 20 mM Tris--HCl at pH 7.4, 1% Triton X-100, 1 mM EDTA, 1.5 mM MgCl 2, 10% glycerol, 150 mM NaCl, 0.1 mM Na 3 VO 4 and 1 Â protease inhibitor cocktail. The protein content of the samples was measured using the BCA protein assay reagent (Pierce). Protein (100 mg) samples were then subjected to SDS --PAGE using 4 --15% Tris--HCl gels and were blot transferred onto a PVDF membrane and immunoblotted with anti-CXCR5, anti-RANKL, anti-c-Myc, anti-p-c-Myc, anti-NFATc3 and anti-ERK/p-ERK antibodies. The bands were detected using the enhanced chemiluminescence detection system. The band intensity was quantified by densitometric analysis using the NIH ImageJ Program (NIH, Bethesda, MD, USA).
SuperArray screening SAKA-T cells (5 Â 10 6 cells per well) were cultured in a 60-mm tissue culture plate with or without CXCL13 (15 ng/ml) for 6 h and total RNA was isolated Confocal microscopy MC3T3-E1 cells were cultured (1 Â 10 3 per well) in Lab-Tek 4-well chamber slides (Nunc, Rochester, NY, USA). Cells were stimulated with and without CXCL13 (15 ng/ml) for 6 h and fixed with 4% paraformaldehyde in PBS for 10 min at room temperature. Cells were permeabilized with 0.1% Triton X-100 for 10 min and blocked for 1 h with PBS containing 2% horse serum at room temperature. Cells were incubated with rabbit anti-p-c-Myc (10 mg/ ml) antibody for 3 h and treated with Alexa 488-conjugated anti-rabbit IgG (Life Technologies, Grand Island, NY, USA) in PBS containing 2% horse serum for 1 h at room temperature. The nuclear staining was performed with DRAQ5 and cellular localization of p-c-Myc was visualized by confocal microscopy (LSM 510; Carl Zeiss, Thornwood, NY, USA).
Chromatin immunoprecipitation assay
ChIP was performed using the ChIP Assay Kit (Upstate, Temecula, CA, USA) following the manufacturer's instructions. Briefly, human bone marrowderived stromal cells (SAKA-T) were stimulated with and without CXCL13 (15 ng/ml) for 6 h. Cells were cross-linked with 1% formaldehyde for 10 min. siRNA interference MC3T3-E1 cells were seeded (5 Â 10 5 cells per well) in 6-well plates and supplemented with a-MEM containing 10% fetal bovine serum. After 1 day of seeding, cells were transfected with double-stranded siRNA (20 nM) against NFATc3 or c-Myc by oligofectamine for 48 h. Non-specific siRNAtransfected cells served as control. Cells were cultured in the presence and absence of CXCL13 (15 ng/ml) for 6 h. Total cell lysates obtained were analyzed by western blot for RANKL, c-Myc and NFATc3 expression using specific antibodies.
Statistical analysis
Results are presented as mean ± s.d. for three independent experiments and compared by Student t-test. Values were considered significant at *Po0.05.
